STP Webinar: Nonclinical Safety Assessment Framework for ADCs and TCEs in Oncology and Non-Oncology

When:  May 15, 2026 from 10:00 to 11:30 (ET)



STP Webinar
Nonclinical Safety Assessment Framework for Antibody-Drug Conjugates (ADCs) and T Cell Engagers (TCEs) in Oncology and Non-Oncology
May 15, 2026 | 10:00 AM–11:30 AM EDT

Hosted by the International Education Subcommittee of the Education Committee and the International Academy of Toxicologic Pathology (IATP) Webinar Committee

This webinar will provide a comprehensive overview of the evolving nonclinical safety assessment frameworks for Antibody–Drug Conjugates (ADCs) and T Cell Engagers (TCEs) in both oncology and non-oncology settings. As these novel therapeutic modalities continue to expand across indications, understanding their unique safety considerations has become increasingly important for toxicologic pathologists and toxicologists worldwide. The session will feature three expert speakers who will cover key areas, including the basic biology and mechanisms of TCEs, current approaches to nonclinical safety assessment for ADCs and TCEs, and regulatory considerations, particularly in the context of autoimmune diseases. This timely and highly relevant webinar is designed to benefit professionals in the United States and internationally by providing practical insights and fostering a deeper understanding of these complex and rapidly advancing therapeutic platforms.

   Moderators:
   Sonika Patial, DVM, MS, PhD, DACVP, DTT/NIEHS
   Shan Naidu, DVM, PhD, DACVP, DABT, Moderna

   Speakers:
   Rebecca Watson, PhD, DABT, Novartis
   Swetha Rudraiah, PhD, US FDA
   Tracey Papenfuss, DVM, PhD, DACVP, StageBio

Webinar Registration >>